CD19 and lymphoma: Meanwhile, in lymphoma, knocking down LSD1 in CD19-CAR T cells can also significantly improve the anti-tumor effect by maintaining the proliferation rate of CD19-CAR T cells, then promote their secretion of IFN-γ, tumor necrosis factor-α (TNF-α) and IL-2, and enhance cytotoxicity and lytic activity 159.